

DAFTAR PUSTAKA

1. Kesehatan K, Penanggulangan K, Nasional K. Panduan Penatalaksanaan Kanker Payudara. 2018 [cited 2022 Feb 21]; Available from: <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
2. WHO. Breast cancer [Internet]. 2021 [cited 2022 Feb 22]. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
3. WHO. WHO South-East Asia region (SEARO). 2020;
4. The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer [Internet]. 2020;858:1–2. Available from: <https://gco.iarc.fr/>
5. Ayuza M, Harahap WA, Rustam R, Nindrea RD. Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018. *J Kesehat Andalas*. 2020;9(1S):65–73.
6. Widiana IK, Irawan H. Clinical and Subtypes of Breast Cancer in Indonesia. *Asian Pacific J Cancer Care*. 2020;5(4):281–5.
7. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 2018;5(2):77.
8. Frank GA, Danilova N V., Andreeva YY, Nefedova NA. WHO Classification of tumors of the breast, 2012. *Arkh Patol*. 2013;75(2):53–63.
9. Abubakar M, Guo C, Koka H, Sung H, Shao N, Guida J, et al. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. *npj Breast Cancer* 2019 51. 2019;5(1):1–9.
10. Al-thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. *Ann Med Surg*. 2020 Jan 1;49:44–8.
11. Harahap WA, Ramadhan, Khambri D, Haryono S, Nindrea RD. Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer. *Asian Pac J Cancer Prev [Internet]*. 2017;18(4):1151–6.
12. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Mol Biol Int [Internet]*. 2014;2014:1–9.
13. Definition of overall survival rate - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2022 Feb 22]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival-rate>
14. Definition of disease-free survival - NCI Dictionary of Cancer Terms -

National Cancer Institute [Internet]. [cited 2022 Feb 22]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/disease-free-survival>

15. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. *Cancer Epidemiol Biomarkers Prev* [Internet]. 2018;27(6):619–26.
16. Bonacho T, Rodrigues F, Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. *Biotech Histochem*. 2020 Feb 17;95(2):71–91.
17. Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Trastuzumab in the Treatment of Breast Cancer. *BioDrugs*. 2016;30(2):75–86.
18. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet (London, England)*. 2017;389(10075):1195–205.
19. Kesehatan K. Pusat Data dan Informasi Kemenkes Bulan Peduli Kanker Payudara [Internet]. 2016 [cited 2022 Feb 22]. Available from: <https://pusdatin.kemkes.go.id/article/view/17013100001/bulan-peduli-kanker-payudara.html>
20. Donna E. Breast Cancer Facts [Internet]. 2020 [cited 2022 Feb 22]. Available from: <https://www.europadonna.org/breast-cancer-facts/>
21. European cancer information system.ECIS. Breast cancer burden in EU-27 2020 new cases (incidence) and deaths (mortality) estimates new cases deaths 1 in 11. *Jt Res Cent*. 2020;44–5.
22. Koufopoulos N, Goudeli C, Syrios J, Filopoulos E, Khaldi L. Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. *Rare Tumors*. 2017;9(3):98–100.
23. Kathrotiya PR, Bridge AT, Warren SJ, Do H, Klenk AS, Xu LY, et al. Primary apocrine adenocarcinoma of the axilla. *Cutis*. 2015;95(5).
24. Zhang H. Pathology Outlines - Metaplastic [Internet]. 2021 [cited 2022 May 12]. Available from: <https://www.pathologyoutlines.com/topic/breastmalignantmetaplastic.html>
25. Zhang S, Wang Y, Gu Y, Zhu J, Ci C, Guo Z, et al. Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns. *Mol Oncol*. 2018;12(7):1047–60.
26. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res*. 2015;5(10):2929.
27. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by

- a panel of four biomarkers using immunohistochemistry. *Breast*. 2012;21(1):50–7.
28. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol*. 2014;5(3):412.
 29. Borges GS, Colchon PH, Staak MC, Girardi F, Rosar KC, Zamboni FM, et al. Analysis of disease-free survival and overall survival in patients with luminal a breast cancer stratified according to TNM. *Klin Onkol*. 2014;27(3):178–82.
 30. Gao JJ, Swain SM. Luminal A Breast Cancer and Molecular Assays: A Review. *Oncologist*. 2018;23(5):556–65.
 31. Waks AG, Winer EP. Breast Cancer Treatment: A Review. *JAMA*. 2019;321(3):288–300.
 32. Puma E, Mariani P, Damian S, Dazzani MC, De Benedictis E, Parati M, et al. Long-Term Overall Survival (OS) and Disease-Free Survival (DFS) According to PCR in Breast Cancers Subtypes: Luminal A and B, Triple Negative and HER2 +, Treated by Neoadjuvant Chemotherapy (NCT). *Ann Oncol*. 2012;23:ix102.
 33. Patel A, Unni N, Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. *Cancers (Basel)*. 2020;12(8):1–17.
 34. Chromosome 17 loci of HER2 and other genes associated with... | Download Scientific Diagram [Internet]. [cited 2022 Feb 22]. Available from: https://www.researchgate.net/figure/Chromosome-17-loci-of-HER2-and-other-genes-associated-with-carcinogenesis-HER2-human_fig2_347930074
 35. Moasser MM. The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene*. 2007;26(45):6469.
 36. Gutierrez C, Schiff R. HER 2: Biology, Detection, and Clinical Implications. *Arch Pathol Lab Med*. 2011;135(1):55.
 37. Bandyopadhyay S, Bluth MH, Ali-Fehmi R. Breast Carcinoma: Updates in Molecular Profiling 2018. *Clin Lab Med*. 2018;38(2):401–20.
 38. Rubin I, Yarden Y. The basic biology of HER2. *Ann Oncol Off J Eur Soc Med Oncol*. 2001;12 Suppl 1(SUPPL. 1).
 39. Findlay VJ, Scholar E. Trastuzumab. *xPharm Compr Pharmacol Ref*. 2021;1–5.
 40. García-Alonso S, Ocaña A, Pandiella A. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. *Trends in Cancer*. 2020;6(2):130–46.
 41. Piccart-Gebhart MJ, Procter M, Sci M, Leyland-Jones B, Goldhirsch A, Untch M, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. *n engl j med*. 2005;353.

42. Definition of disease-free survival - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2022 Feb 23]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/disease-free-survival>
43. Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, et al. De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost? *Int J Radiat Oncol Biol Phys*. 2020;108(4):1040–6.
44. Zhou YH, Liu Y, Zhang W, Liu C, He JJ, Tang XJ. Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer. *Pathol - Res Pract*. 2019;215(11):152644.
45. Age [Internet]. [cited 2022 Jun 27]. Available from: <https://www.breastcancer.org/risk/risk-factors/age>
46. Prawirohardjo S. Ilmu Kandungan. 2011;
47. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. *Breast Cancer Res Treat*. 2008;107(3):309–30.
48. Tumor Staging and Grading: A Primer. *Molecular Profiling*, 1–17 | 10.1007/978-1-4939-6990-6_1. [cited 2022 Nov 12]. Available from: https://sci-hub.se/https://doi.org/10.1007/978-1-4939-6990-6_1
49. Zheng K, Tan JX, Li F, Li HY, Zeng XH, Ma BL, et al. Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients. *Transl Oncol*. 2018;11(4):1023.
50. View of Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS) [Internet]. [cited 2022 Jun 26]. Available from: <https://www.riverpublishersjournal.com/index.php/MCT/article/view/12/8>
51. ANALISIS SURVIVAL PASIEN KANKER PAYUDARA HER 2(+3) DI PADANG TAHUN 2010-2015 - eSkripsi Universitas Andalas [Internet]. [cited 2022 Jun 26]. Available from: <http://scholar.unand.ac.id/30751/>
52. Disease Free Survival, Kualitas Hidup Dan Direct Medical Cost Penderita Kanker Payudara Her2 Positif Stadium Awal Yang Menjalani Kemoterapi Adjuvan Anti Her2 Di Rsup Dr Sardjito 2007-2014 [Internet]. [cited 2022 Jun 26]. Available from: <http://etd.repository.ugm.ac.id/penelitian/detail/102736>
53. Boekhout AH, Beijnen JH, Schellens JHM. Trastuzumab. *Oncologist*. 2011;16(6):800.
54. Camejo N, Castillo C, Alonso R, Correa F, Rivero E, Mezquita C, et al. Effectiveness of Trastuzumab for Human Epidermal Growth Factor

Receptor 2-Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations. *JCO Glob Oncol*. 2020;6:217–23.

55. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. *Lancet*. 2019;393(10191):2591–8.
56. Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. *Health Technol Assess*. 2020;24(40):1–230.

